Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synaptophysin autoantibodies mediate synaptic dysfunction in cerebellar ataxia.

Cell reports. Medicine·2026
Same author

Triggering multiple sclerosis: infection with Epstein-Barr virus activates multiple pre-existing autoreactive B and T cells.

Signal transduction and targeted therapy·2026
Same author

CD20+ natural killer cells are polyfunctional, memory-like cells that are enriched in inflammatory disorders.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

BTK-Inhibition Enhances TLR-7-Mediated Interferon-Alpha Production in pDCs by Blocking the Inhibitory BDCA-2 Pathway.

European journal of immunology·2025
Same author

Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders.

Multiple sclerosis and related disorders·2025
Same author

B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.

International journal of molecular sciences·2024

Related Experiment Video

Updated: May 26, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Untapped targets in multiple sclerosis.

Edgar Meinl1

  • 1Institute of Clinical Neuroimmunology, Ludwig-Maximilians University, Munich and Department of Neuroimmunology, Max-Planck-Institute of Neurobiology, Martinsried, Germany.

Journal of the Neurological Sciences
|December 31, 2011
PubMed
Summary

Multiple sclerosis (MS) involves immune attacks on the brain and spinal cord, causing nerve damage. Research is identifying specific autoimmune targets to develop precise treatments for MS patients.

More Related Videos

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices
06:36

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

Published on: February 5, 2015

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Related Experiment Videos

Last Updated: May 26, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices
06:36

An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

Published on: February 5, 2015

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

  • Neuroimmunology
  • Neurology
  • Pathology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory disease affecting brain white and grey matter, leading to irreversible axonal and neuronal damage.
  • Grey matter injury in MS significantly contributes to disability, often more than white matter lesions.
  • Understanding MS immunopathology is crucial for identifying new therapeutic targets.

Purpose of the Study:

  • To explore the immunopathology of multiple sclerosis (MS).
  • To identify specific autoimmune targets involved in MS pathogenesis.
  • To pave the way for developing targeted therapies for MS.

Main Methods:

  • Review of current research on MS immunopathology.
  • Analysis of animal models to understand disease mechanisms.
  • Identification of autoantibodies and T cell specificities in MS patients.

Main Results:

  • A two-step pathological process in MS involves T cells, inflammation, blood-brain barrier disruption, and antibody-mediated damage.
  • Autoantibodies against aquaporin-4 and MOG antibodies are implicated in related diseases.
  • Axoglial antigens like neurofascin and contactin-2/TAG-1 are identified as autoimmune targets in MS, potentially causing axonal injury and grey matter pathology.

Conclusions:

  • Identifying specific autoimmune targets in MS is a key research focus.
  • Discovering patient subgroups based on autoreactivity may enable personalized treatments.
  • Future research aims to develop safe and effective therapies targeting specific MS pathologies.